Serum Institute of India Pvt. Ltd. · 细胞治疗 · 细胞治疗
meningococcal A conjugate vaccine 是一种细胞治疗，由Serum Institute of India Pvt. Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。
| 商品名 | MenAfriVac |
| 公司 | Serum Institute of India Pvt. Ltd. |
| 药物类别 | 细胞治疗, 疫苗 |
| 给药途径 | Injectable (Others), Intramuscular (IM) Injection |
| 状态 | Approved |
meningococcal A conjugate vaccine 针对 1 个适应症，涉及 1 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Infections and infestations | Meningococcal bacteraemia | ✓ Approved |
Nguyen Quynh-Giao QG, Abdullah Rohat Muhyadeen RM, Hassan Eman Fathy Abdeltwab EFA, Dang Van Tri VT et al.
He Wenxin W, Song Qijun Q, Liu Qingyuan Q, Chen Xingyue X et al.
In this study, bovine serum albumin-γ-cyclodextrin (BSA-CD) conjugate was prepared to explore its solubilization effect on Paclitaxel (PTX) and the underlying mechanism. The aqueous solubility studies revealed that when 0.1 mM BSA-CD conjugate was complexed with 4 mM PTX, the maximum aqueous solubility of PTX reached 34 mM, which was approximately 5-fold higher than that of the clinical formulation Abraxane™, with drug loading capacity increased by about 2.8-fold. In vitro release studies demonstrated that the inclusion complex exhibited a cumulative PTX release of approximately 14% over 72 h at pH 7.4 and approximately 23% at pH 5.5, indicating a pH-responsive release profile. MTT assays confirmed that the BSA-CD carrier was non-cytotoxic, and the inclusion complex at the concentration of 10 μM exhibited superior cytotoxicity against melanoma B16F10 cells compared to free PTX and Abraxane™. This study confirms that the BSA-CD conjugate, through the synergistic "dual encapsulation" effect of the BSA hydrophobic pocket and the γ-CD hydrophobic cavity combined with a moderately aggregated state modulated by specific ionic strength, significantly enhances the aqueous solubility and delivery efficiency of PTX, providing a novel and efficient carrier as well as new insights for the formulation optimization of hydrophobic anticancer drugs.
Ji Pengwei P, Yang Xingdie X, Ling Weibo W, Zhang Songnan S et al.
As important bioisosteres of α-amino acids, chiral α-aminophosphonic acids exhibit broad bioactivities and are widely employed in pharmaceuticals. Direct asymmetric α-C conjugate addition of aminomethylphosphonate to α,β-unsaturated ketones is an intriguing strategy to make bioactive chiral phosphonic 1-pyrrolines. However, this transformation remains challenging due to the low α-C-H acidity of the aminomethylphosphonate, significant steric hindrance from the phosphonate moiety and interference by side reactions. In this work, we report the direct enantioselective α-C conjugate addition of NH2-unprotected aminomethylphosphonate to α,β-unsaturated ketones, by applying an organo-organo double activation strategy that employs pyridoxal to activate aminomethylphosphonates into reactive carbanions, while concurrently using pyrrolidine to convert α,β-unsaturated ketones into active iminium species. Various chiral phosphonic 1-pyrrolines are synthesized in high yields with excellent diastereo- and enantioselectivity (up to 99% yield, > 20:1 dr, 99% ee). Furthermore, the methodology can be extended to a one-pot sequential synthesis of structurally diverse quaternary α-aminophosphonate derivatives.
Ky Samantha L SL, Coblentz Evan G EG, Swanson Emma E, Shah Rhea R et al.
Human papillomavirus (HPV) is the most common sexually transmitted infection among people ages 15-24 years in the U.S. However, many individuals remain unvaccinated against HPV. Recommendations from friends and family have been shown to improve vaccine uptake and should be encouraged. This study aimed to determine if the provision of vaccine-related information would change the likelihood of recommending the HPV vaccine to their peers. Furthermore, we examined characteristics associated with a positive change. Participants were recruited at two no-cost vaccine clinics on a university campus in September and October 2024. Through a one-time, voluntary, online survey, participants were asked how likely they were to recommend the HPV vaccine to a family or friend on a scale from 1 (very unlikely) to 5 (very likely). This question was repeated after they were provided with a list of diseases that are prevented by the HPV vaccine. We conducted dependent samples t-tests to determine if there was a change in recommendation scores before and after information provision. We also conducted bivariate (chi-square and independent t-tests) and multivariable (logistic regression) analyses to examine factors associated with a positive change versus no/negative change. The final sample (n = 556) were majority White (n = 310, 55.8%), female (n = 331, 59.5%), and college students (n = 480, 86.5%). The average post-information provision (Mean = 4.21; SD = 0.95) recommendation score was significantly higher than the pre-information provision (Mean = 3.87; SD = 1.031) recommendation score (t = -11.37; p < 0.001). In multivariable logistic regression analyses, there was a statistically significant positive change in recommendation score with younger age (aOR = 0.98, 95% CI = 0.95-1.00) and lower vaccine confidence (aOR = 0.50, 95%CI = 0.36-0.68). This indicates that targeted interventions to improve awareness of diseases prevented by the HPV vaccine could be particularly effective in populations that are younger or have lower vaccine confidence.
Din Miraj Ud MU, Ahmad Sajjad S, Liu Xiaohui X, Jiang Hui H et al.
One of the primary factors in the development of cancer is the accumulation of genetic mutations. Some of these genetic mutations result in the emergence of unique antigens called neoantigens. These neoantigens are perceived as non-self by T cells, making them prime targets for cancer vaccines. These neoantigen-based vaccines can elicit a promising immune response against the malignant cells. In the current research work, a computational approach was employed to design a multi-epitope vaccine for glioblastoma. A set of 126 neoantigens was retrieved from the CEDAR cancer epitopes database which yielded 446 epitopes. The epitopes were screened and 10 potential epitopes were selected to design a multi-epitope vaccine. GPGPG linkers were used for combining these epitopes, while adjuvants were connected to the vaccine via EAAAK and RVRR linkers to build the final construct of the vaccine. The physicochemical properties of the vaccine indicated that the designed vaccine is highly antigenic (0.7841 antigenicity score), non-allergenic, non-toxic, and also water soluble. Molecular docking assessed the interaction of the vaccine with MHC-I, MHC-II, and TLR-4, demonstrating strong binding affinities (-886.5 kcal/Mol, -1050.2 kcal/Mol, and - 1018.3 kcal/Mol, respectively). The docking results were further supported by the normal mode analysis and molecular dynamics simulation showing average RMSD values of 4.21 Å, 6.80 Å, and 5.68 Å for the three complexes, respectively. The in silico cloning of the vaccine into the bacterial plasmid (pET28a+) was carried out to enhance its expression achieving a GC content of 57.43 and a codon adaptation index of 1. The in silico immune simulation revealed that peak antigen levels (∼7.5 × 105 counts/mL at approximately day 50) elicited strong humoral and cellular immune responses, characterized by elevated IgM + IgG titers (∼2.8 × 105) and increased cytokine production, including IFN-γ (∼4.5 × 105), IL-2 (∼6.0 × 105), and TNF-α (∼1.2 × 105 ng/mL), indicating robust immune activation. These findings indicated that our designed vaccine could be a potential therapeutic candidate against glioblastoma. Further experimental research is required to validate the potential, efficacy, and safety of the designed vaccine.
Razzaghi Hilda H, Garacci Emma E, Kahn Katherine E KE, Meghani Mehreen M et al.
To assess end-of-season coverage with influenza, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), and COVID-19 vaccines among pregnant women, and respiratory syncytial virus (RSV) immunization among pregnant women and their infants, during the 2024-25 respiratory illness season. Data from an Internet panel survey conducted during March 26-May 8, 2025, were analyzed. The study included 2738 currently and recently pregnant women; analysis of each immunization product was restricted to a subsample of participants eligible for the specific product (influenza: 1788; Tdap: 885; COVID-19: 2125; maternal RSV: 721; nirsevimab: 1416). Coverage was assessed for individual vaccines, along with demographic characteristics, provider recommendation for immunization, and attitudes, including perceptions on safety and effectiveness of vaccines. Differences in vaccination coverage between groups were assessed using t-tests. Among eligible participants, 51.0% reported receiving influenza vaccine before or during pregnancy, 52.6% reported receiving Tdap vaccine during pregnancy, 32.3% reported receiving the 2024-25 COVID-19 vaccine before or during pregnancy, and 49.3% reported receiving an RSV vaccine during pregnancy. Among 1416 women with eligible infants, 62.2% reported their infant received nirsevimab; overall, 70.4% of infants were protected by maternal RSV vaccine, nirsevimab, or both. Vaccination coverage was higher among women with a provider recommendation compared to those without for influenza (65.6% vs. 12.2%), Tdap (69.5% vs. 2.9%), and COVID-19 (56.4% vs. 4.4%) vaccines. Prevalence of provider recommendation for Tdap vaccination was lower among non-Hispanic Black (66.4%) and Hispanic women (60.1%) compared with non-Hispanic White women (83.2%). Women reporting being very/somewhat hesitant about a given vaccine were less likely than non-hesitant women to have received that vaccine. Provider recommendation and vaccine hesitancy were associated with maternal vaccine uptake. Because providers have been found to be trusted information sources for patients, efforts supporting informative vaccine conversations between providers and pregnant women could help increase the proportion of pregnant women and infants protected against severe respiratory illnesses.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →